Stifel Reiterates Hold Rating on Nektar Therapeutics (NKTR) on Cost Restructuring, Sees NKTR-358 as "Growth Driver Going Forward"
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Hold rating and $4.70 price target on Nektar Therapeutics (NASDAQ: NKTR) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
